UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 慢性腎疾患における高リン血症の治療 treatment of hyperphosphatemia in chronic kidney disease
- 2. 慢性腎臓病における血管石灰化 vascular calcification in chronic kidney disease
- 3. 小児における、慢性腎臓病に伴う骨ミネラル代謝異常（CKD-MBD） pediatric chronic kidney disease mineral and bone disorder ckd mbd
- 4. 慢性腎臓疾患に関連する無形成骨症 adynamic bone disease associated with chronic kidney disease
- 5. 慢性腎疾患を有する透析前の成人患者における二次性副甲状腺機能亢進症およびミネラル代謝異常のマネージメント management of secondary hyperparathyroidism and mineral metabolism abnormalities in adult predialysis patients with chronic kidney disease
English Journal
- Adsorption of As(III) and As(V) onto colloidal microparticles of commercial cross-linked polyallylamine (Sevelamer) from single and binary ion solutions.
- Kyzas GZ1, Siafaka PI1, Kostoglou M1, Bikiaris DN2.
- Journal of colloid and interface science.J Colloid Interface Sci.2016 Jul 15;474:137-45. doi: 10.1016/j.jcis.2016.04.027. Epub 2016 Apr 20.
- This work investigates the removal of arsenic ions in trivalent (As(III)) or pentavalent form (As(V)) from single-component and binary (equal initial ion concentrations) aqueous solutions using commercial cross-linked polyallylamine (namely as Sevelamer) as adsorbent. This is the first work in liter
- PMID 27124807
- Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go.
- Rizk R1.
- BMC nephrology.BMC Nephrol.2016 Jul 8;17(1):75.
- Hyperphosphatemia management is integral to the management of patients with chronic kidney disease. This mineral abnormality is associated with greater costs, but so is its management, especially with the use novel phosphate binders. The economic evaluation of these pharmaceutical agents is increasi
- PMID 27393192
- Preclinical studies of VS-505: a non-absorbable highly effective phosphate binder.
- Wu-Wong JR1, Chen YW1, Wong JT2, Wessale JL1.
- British journal of pharmacology.Br J Pharmacol.2016 Jul;173(14):2278-89. doi: 10.1111/bph.13510. Epub 2016 Jun 12.
- BACKGROUND AND PURPOSE: Phosphate imbalance is often present in chronic kidney disease (CKD), and it contributes to a higher cardiovascular mortality rate. A phosphate binder is typically part of a treatment strategy for controlling phosphate imbalance. However, safety concerns and low compliance ar
- PMID 27156057
Japanese Journal
- Treatment of hyperphosphatemia in hemodialysis patients : The Calcium Acetate Renagel Evaluation (CARE Study)
- QUNIBI WY
- Kidney Int 65, 1914-1926, 2004
- NAID 30014590239
- Sevelamer hydrochloride (Renagel^<○!R>), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency
- NAGANO N
- Nephrol Dial Transplant 16, 1870-1878, 2001
- NAID 30018452153
Related Links
- Indication for Renvela and Renagel Renvela ® (sevelamer carbonate) and Renagel ® (sevelamer hydrochloride) are indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.
- Learn about the prescription medication Renagel (Sevelamer Hcl), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. ... What are the possible side effects of sevelamer (Renagel, Renvela)? Get ...
Related Pictures
